It is also the first drug approved to treat both pituitary- and adrenal-dependent Cushing's in dogs. This prescription drug works by stopping the production of cortisol in the adrenal glands.<ref>{{cite web|url=http://caninediabeteswiki.wikkii.com/w/images/caninediabeteswiki/uploads/8/87/2006symposiumproceedings.pdf|title=Trilostane-5 Years of Clinical Experience for the Treatment of Cushing's Disease|author=Reusch, Claudia E.|year=2006|publisher=Ohio State University Endocrinology Symposium|pages=17–19|accessdate=5 April 2011}} ([[PDF]])</ref><ref>{{cite web|url=http://www.vin.com/proceedings/Proceedings.plx?CID=WSAVA2010&Category=&PID=56127&O=Generic|title=Trilostane-A Review of a Success Story|author=Reusch, Claudia E.|year=2010|publisher=World Small Animal Veterinary Association (WSAVA)|accessdate=5 April 2011}}</ref> In studies of the drug, the most common side effects were vomiting, lack of energy, diarrhea, and weight loss. Trilostane should not be given to a dog that:

 
It is an [[enzyme inhibitor|inhibitor]] of [[3β-hydroxysteroid dehydrogenase]] (3β-HSD), as well as of other [[enzyme]]s involved in [[steroidogenesis]].<ref name="pmid21295836">{{cite journal |author1=de Gier J |author2=Wolthers CH |author3=Galac S |author4=Okkens AC |author5=Kooistra HS |title=Effects of the 3β-hydroxysteroid dehydrogenase inhibitor trilostane on luteal progesterone production in the dog |journal=Theriogenology |volume=75 |issue=7 |pages=1271–9 |date=April 2011 |pmid=21295836 |doi=10.1016/j.theriogenology.2010.11.041 |url=http://linkinghub.elsevier.com/retrieve/pii/S0093-691X(10)00634-5}}</ref>

 
*[http://caninediabeteswiki.wikkii.com/w/images/caninediabeteswiki/uploads/a/ab/SPC_183023.pdf Trilostane (Vetoryl) information from Veterinary Medicines Directorate, UK].  Includes precautionary use regarding concurrent medical conditions, possible side effects, and possible interaction with other drugs. ([[PDF]])
